Key Takeaways
- The global cell and gene therapy pipeline reached 1,040 active clinical programmes in Q1 2026, a 34% increase from two years prior, with oncology indications accounting for 61% of that total.
- Only 14 cell or gene therapies received regulatory approval across the US, EU, and UK in the 24 months to April 2026, representing a conversion rate well below 2% of active programmes.
- Manufacturing capacity remains the single largest commercial bottleneck: a 2025 survey of 112 CGT executives found 68% cited batch failure rates and scale-up costs as the primary obstacles to launch.
- Payer reimbursement frameworks have not kept pace with one-time curative pricing models, with fewer than 30% of approved CGT products securing broad national coverage within 18 months of approval.
One thousand and forty. That is the number of cell and gene therapy programmes now active in clinical development worldwide, according to Q1 2026 pipeline data compiled across the major regulatory jurisdictions. Two years ago, the figure stood at 776. The pace of entry into trials has not slowed. What has slowed, with increasing visibility, is the rate at which those programmes translate into commercially viable products. Fourteen approvals across the US, EU, and UK in 24 months sounds respectable until set against a pipeline of four figures. The industry is producing scientific ambition at record scale. The infrastructure to realise that ambition commercially is lagging by almost every measurable metric.
Manufacturing Is Where Pipelines Go to Stall
A 2025 survey of 112 executives at cell and gene therapy developers, conducted by a specialist CMO advisory firm, found that 68% ranked manufacturing scale-up as their primary commercialisation obstacle, ahead of regulatory uncertainty (54%) and payer access (49%). The underlying problem is structural: autologous therapies, which account for roughly 43% of the active pipeline, require patient-specific production runs with batch sizes of one. Failure rates at commercial scale routinely exceed 15%, and the fully loaded cost of a single failed batch at a large autologous CAR-T facility can reach $400,000. For companies without the balance sheet to absorb repeated failures, that arithmetic closes off the commercial path entirely.
Allogeneic platforms were supposed to resolve the manufacturing equation by enabling off-the-shelf production at scale. Progress has been slower than projected. As of Q1 2026, only 9 allogeneic cell therapies had reached Phase III globally, compared with 31 autologous programmes at the same stage. Potency and persistence challenges, particularly in the solid tumour setting, continue to constrain the allogeneic value proposition. The manufacturing problem has not been designed away; it has been deferred.
Regulatory Convergence Has Been Partial at Best
The EU's reformed Advanced Therapy Medicinal Products framework, updated in 2024, was intended to streamline approval timelines and reduce duplicative data requirements for developers operating across multiple markets. In practice, the benefits have been uneven. A cross-jurisdictional analysis published in February 2026 found that median time from first regulatory submission to final approval for CGT products in the EU was 28 months, compared with 19 months in the US under accelerated pathways. The divergence is partly definitional: EU regulators apply stricter manufacturing consistency standards at the point of approval rather than post-market, which adds time but reduces post-approval remediation risk.
"We have programmes that are scientifically best-in-class and clinically compelling, but the regulatory dossier for a gene therapy of this complexity is a different order of magnitude from a small molecule. The timelines are not set up for the science we are now capable of producing."
Payer Models Are Structurally Misaligned with One-Time Therapies
The reimbursement problem is not new, but it is worsening as the volume of approved products increases. Fewer than 30% of cell and gene therapies approved in the US or EU between 2022 and 2025 had secured broad national coverage within 18 months of approval. Outcomes-based contracts, once positioned as the solution to high upfront pricing, have proven difficult to execute at scale: a 2025 analysis of 23 CGT outcomes agreements in Europe found that fewer than half included reliable long-term follow-up mechanisms, undermining the data infrastructure needed to validate payments. List prices for approved gene therapies continue to exceed $2 million per patient in several indications, a figure that national health systems in mid-income markets cannot absorb under current frameworks.
The bottlenecks concentrating in the CGT sector reduce to three compounding failures, each reinforcing the others:
- Manufacturing readiness: Developers are entering clinical trials without credible commercial-scale production strategies, deferring the hardest engineering problems to a point where failure carries maximum financial consequence.
- Regulatory sequencing: Jurisdictional divergence on manufacturing standards and data requirements is forcing duplicative investment in parallel dossiers, disproportionately disadvantaging smaller developers without global regulatory infrastructure.
- Payer engagement timing: Health technology assessment bodies are being engaged too late, after pivotal trial design is fixed, resulting in evidence packages that satisfy regulators but leave payers without the comparative effectiveness data they need to justify reimbursement.
The strategic implication for the sector is sharp and overdue. A pipeline of 1,040 programmes is not an unambiguous indicator of industry health. It is, in part, a measure of how many organisations have cleared the scientific threshold for clinical entry without clearing the commercial threshold for sustainable launch. The next phase of CGT development will not be won in the laboratory. It will be won by developers who treat manufacturing strategy, regulatory sequencing, and payer engagement as design constraints from the point of programme inception, not as problems to solve once clinical data lands.
